Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2017, Article ID 7089702, 7 pages
Research Article

Gamma-Glutamyl Transpeptidase-to-Platelet Ratio Predicts Significant Liver Fibrosis of Chronic Hepatitis B Patients in China

1Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin 130021, China
2Jilin Province Key Laboratory of Infectious Disease, Laboratory of Molecular Virology, Changchun 130021, China
3Key Laboratory of Zoonosis Research, Ministry Education, Changchun, Jilin 130021, China

Correspondence should be addressed to Junqi Niu; moc.361@uin_iqnuj

Received 6 December 2016; Revised 15 March 2017; Accepted 22 May 2017; Published 31 July 2017

Academic Editor: Fabio Marra

Copyright © 2017 Tianyi Ren et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background and Aims. We want to investigate whether a novel noninvasive marker is suitable for Chinese CHB patients. Methods. A total of 160 treatment-naïve CHB patients who underwent liver biopsy were enrolled in our study, and we assessed the diagnostic accuracies of GPR, aspartate transaminase-to-platelet ratio index (APRI), and the fibrosis index based on 4 factors (FIB-4) in them. Results. Of these 160 CHB patients, the numbers of F0, F1, F2, F3, and F4 are 34 (21.3%), 62 (38.8%), 18 (11.3%), 24 (15%), and 22 (13.8%), respectively. The area under the receiver operating characteristic curves (AUROC) of GPR for fibrosis (0.77 versus 0.70, ), significant fibrosis (0.70 versus 0.63, ), and extensive fibrosis (0.71 versus 0.64, ) were significantly higher than those of APRI. The AUROCs of GPR and Fib-4 for fibrosis (0.77 versus 0.75, ), significant fibrosis (0.70 versus 0.70, ), extensive fibrosis (0.71 versus 0.68, ), and cirrhosis (0.64 versus 0.67, ) were comparable. Conclusions. The GPR can be a routine laboratory marker to stage liver fibrosis in patients with CHB in China.